Expertise in
10
conditions

Dr. Carl Minniti

Hematology | Oncology
The Minniti Center For Oncology And Hematology
174 Democrat Rd, 
Mickleton, NJ 
Expertise in
10
conditions
The Minniti Center For Oncology And Hematology
174 Democrat Rd, 
Mickleton, NJ 

Overview

Carl Minniti is a Hematologist and an Oncologist practicing medicine in Mickleton, New Jersey.

Dr. Minniti is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Merkel Cell Carcinoma.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 27 clinical trials.

Specialties

Hematology
Oncology

Licenses

Specialist in NJ

Hospital Affiliations

Inspira Medical Center Vineland
Hospital Of Univ Of Pennsylvania
Inspira Medical Center Mullica Hill

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

The Minniti Center For Oncology And Hematology
174 Democrat Rd, Mickleton, NJ 08056
Other Locations
The Minniti Center for Medical Oncology and Hematology
174 Democrat Rd, Mickleton, NJ 08056

Additional Areas of Focus

Dr. Minniti has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Paclitaxel
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Drosophila muller f elements maintain a distinct set of genomic properties over 40 million years of evolution.
Drosophila muller f elements maintain a distinct set of genomic properties over 40 million years of evolution.
Journal: G3 (Bethesda, Md.)
Published: March 06, 2015
Similar Doctors
Expertise in
7
conditions
Dr. Tami L. Bach
Hematology | Oncology
Expertise in
7
conditions
Dr. Tami L. Bach
Hematology | Oncology
Referral may be required
Before you request

The Minniti Center For Oncology And Hematology

174 Democrat Rd, 
Mickleton, NJ 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tami Bach is a Hematologist and an Oncologist practicing medicine in Mickleton, New Jersey. Dr. Bach is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, and Thrombocytopenia. Dr. Bach is board certified in Medical Oncology, 2007 and Hematology, 2004. Dr. Bach is currently accepting new patients.

Expertise in
8
conditions
Dr. Kevin J. Callahan
Hematology | Anesthesiology
Expertise in
8
conditions
Dr. Kevin J. Callahan
Hematology | Anesthesiology
Referral may be required

Cooper Primary And Specialty Care At Thorofare

196 Grove Ave, Suite C, 
West Deptford, NJ 
 (4.9 miles away)
856-848-7577
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Callahan is a Hematologist and an Anesthesiologist practicing medicine in West Deptford, New Jersey. Dr. Callahan is highly rated in 8 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, End-Stage Renal Disease (ESRD), Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome. Dr. Callahan is board certified in American Osteopathic Board Of Internal Medicine,Oncology , 1994 and American Osteopathic Board Of Internal Medicine,Internal Medicine , 1991. Dr. Callahan is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Inspira Medical Group Hematology / Medical Oncology Mullica Hill

698 Mullica Hill Rd Ste 300, 
Mullica Hill, NJ 
 (6.4 miles away)
856-508-3575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erev Tubb is an Oncologist practicing medicine in Mullica Hill, New Jersey. Dr. Tubb is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Angiosarcoma, Multiple Myeloma, and Pleuropulmonary Blastoma.

Expertise in
46
conditions
Dr. Brian S. Wojciechowski
Hematology | Oncology
Expertise in
46
conditions
Dr. Brian S. Wojciechowski
Hematology | Oncology
Referral may be required

Prospect CCMC LLC

1 Medical Center Blvd, 
Chester, PA 
 (6.8 miles away)
610-876-5166
Languages Spoken:
English
See accepted insurances

Brian Wojciechowski is a Hematologist and an Oncologist practicing medicine in Chester, Pennsylvania. Dr. Wojciechowski is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Multiple Myeloma, and Pleuropulmonary Blastoma.

Expertise in
5
conditions
Expertise in
5
conditions
Referral may be required
Before you request

HMH - Integrative Health And Medicine - Red Bank

1 Riverview Plaza, Floor 2, 
Red Bank, NJ 
 (6.6 miles away)
732-263-7999
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Israel is an Oncologist practicing medicine in Red Bank, New Jersey. Dr. Israel is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Opioid Induced Constipation, Liver Failure, Plaque Psoriasis, Adenoid Cystic Carcinoma, and Prostatectomy. Dr. Israel is currently accepting new patients.

Expertise in
7
conditions
Expertise in
7
conditions
Referral may be required
Before you request

Riverview Medical Center

1 Riverview Plaza, Cancer Center, 
Red Bank, NJ 
 (6.6 miles away)
732-576-8610
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raghu Kunamneni is a Hematologist practicing medicine in Red Bank, New Jersey. Dr. Kunamneni is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, and Myelodysplastic Syndrome (MDS). Dr. Kunamneni is board certified in American Board Of Internal Medicine. Dr. Kunamneni is currently accepting new patients.

Frequently Asked Questions about Dr. Carl Minniti

How do I make an appointment with Dr. Carl Minniti?

You can book an appointment with Dr. Carl Minniti by calling their office at 856-423-0754. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carl Minniti a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carl Minniti is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carl Minniti specialize in?

While Dr. Carl Minniti is a Hematology, they have specific expertise in Breast Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Carl Minniti participate in research or clinical trials?

Yes. Dr. Carl Minniti has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Carl Minniti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carl Minniti accept my insurance?

Dr. Carl Minniti accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 856-423-0754 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Minniti's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 57 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile